Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban and Aspirin in PAD after Endovascular Revascularization
NCT05308030Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in Peripheral Arterial Disease (PAD), sponsored by Assiut University. Primary endpoint: Patency at 1 year. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT05308030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308030.